Breaking News

Quivive, Camargo Partner on 505(b)(2) Combo Products

Camargo to provide regulatory consulting and strategic development services for Quivive's pipeline

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Quivive Pharma, a biopharma company developing next generation opioid therapies, has entered into service agreements with Camargo Pharmaceutical Services to provide regulatory consulting and strategic development services for Quivive’s pipeline of fixed-dose combination products using its abuse-deterrent technology platform. The first program will concentrate on an abuse-deterrent immediate-release 505(b)(2) combination of hydrocodone and an approved respiratory stimulant.  Camargo s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters